Novartis announces five-year data that reinforce the safety and efficacy profile of Aimovig® (erenumab-aooe) in adult patients with episodic migraine
- Saturday, October 3, 2020, 7:01
- Finance
- Add a comment
EAST HANOVER, N.J., Oct. 3, 2020 /PRNewswire/ — Novartis today announced that results reinforcing the long-term safety and efficacy profile of Aimovig® (erenumab-aooe) in patients with episodic migraine (EM) are being presented at the Migraine Trust Virtual Symposium. Results from the…
About the Author
adminasapcorp has written 39704 stories on this site.